Protagonist Therapeutics' CEO on its hepcidin memetic at #ASH23 and oral IL23 program in I&I

Previewing Sunday (Day 2) of the ASH Annual Meeting with ApexOnco's Madeleine Armstrong

Arcellx's CEO on Friday's #ASH23 topline release and his take on the BCMA field

Mizuho Senior Analyst Mara Goldstein previews the #ASH23 Annual Meeting

Taking a deep dive into atopic dermatitis with the CEO of Apogee Therapeutics

YC Health & Bio Summit: Menlo Ventures' Greg Yap on life sciences, AI, and advice for founders

YC Health & Bio Summit: Y Combinator's Group Partner for Health and Biotech describes how YC works

Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Mapping autism spectrum disorder protein interactions with the director of UCSF's QBI

William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area

SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

Sofinnova Investments' Jakob Dupont on the private markets in biotech

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

Next generation T-cell engineering with ArsenalBio

BMO's Evan Seigerman joins Analyst Thursdays from London

An exclusive look at the Cellares Cell Shuttle automated cell therapy manufacturing system

Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays

PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria